Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) and Cardiac Arrhythmias: A Systematic Review and Meta-analysis

Cardiovasc Diabetol.

SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending the use of SGLT2i in patients with DM, CKD, and HF. Further research is needed to fully elucidate the mechanism by which SGLT2i protect against arrhythmias.